Literature DB >> 19342505

Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays.

Matthew D Krasowski1, Mohamed G Siam, Manisha Iyer, Anthony F Pizon, Spiros Giannoutsos, Sean Ekins.   

Abstract

BACKGROUND: Immunoassays used for routine drug of abuse (DOA) and toxicology screening may be limited by cross-reacting compounds able to bind to the antibodies in a manner similar to the target molecule(s). To date, there has been little systematic investigation using computational tools to predict cross-reactive compounds.
METHODS: Commonly used molecular similarity methods enabled calculation of structural similarity for a wide range of compounds (prescription and over-the-counter medications, illicit drugs, and clinically significant metabolites) to the target molecules of DOA/toxicology screening assays. We used various molecular descriptors (MDL public keys, functional class fingerprints, and pharmacophore fingerprints) and the Tanimoto similarity coefficient. These data were then compared with cross-reactivity data in the package inserts of immunoassays marketed for in vitro diagnostic use. Previously untested compounds that were predicted to have a high probability of cross-reactivity were tested.
RESULTS: Molecular similarity calculated using MDL public keys and the Tanimoto similarity coefficient showed a strong and statistically significant separation between cross-reactive and non-cross-reactive compounds. This result was validated experimentally by discovery of additional cross-reactive compounds based on computational predictions.
CONCLUSIONS: The computational methods employed are amenable toward rapid screening of databases of drugs, metabolites, and endogenous molecules and may be useful for identifying cross-reactive molecules that would be otherwise unsuspected. These methods may also have value in focusing cross-reactivity testing on compounds with high similarity to the target molecule(s) and limiting testing of compounds with low similarity and very low probability of cross-reacting with the assay.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342505      PMCID: PMC2855823          DOI: 10.1373/clinchem.2008.118638

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  31 in total

1.  Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures.

Authors:  Jérôme Hert; Peter Willett; David J Wilton; Pierre Acklin; Kamal Azzaoui; Edgar Jacoby; Ansgar Schuffenhauer
Journal:  Org Biomol Chem       Date:  2004-09-29       Impact factor: 3.876

Review 2.  Molecular similarity: a key technique in molecular informatics.

Authors:  Andreas Bender; Robert C Glen
Journal:  Org Biomol Chem       Date:  2004-10-14       Impact factor: 3.876

3.  Diversity in hapten recognition: structural study of an anti-cocaine antibody M82G2.

Authors:  Edwin Pozharski; Aaron Moulin; Anura Hewagama; Armen B Shanafelt; Gregory A Petsko; Dagmar Ringe
Journal:  J Mol Biol       Date:  2005-04-21       Impact factor: 5.469

4.  Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring.

Authors:  Qiang Zhang; Ingo Muegge
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

5.  Buflomedil is a potent interfering substance in immunoassays of tricyclic antidepressants.

Authors:  P Mura; P Kintz; R Robert; Y Papet
Journal:  J Anal Toxicol       Date:  1998 May-Jun       Impact factor: 3.367

6.  Comparison of assay methods for benzodiazepines in urine. A receptor assay, two immunoassays, and gas chromatography-mass spectrometry.

Authors:  T Nishikawa; H Ohtani; D A Herold; R L Fitzgerald
Journal:  Am J Clin Pathol       Date:  1997-03       Impact factor: 2.493

7.  Interference with testing for lysergic acid diethylamide.

Authors:  D Ritter; C M Cortese; L C Edwards; J L Barr; H D Chung; C Long
Journal:  Clin Chem       Date:  1997-04       Impact factor: 8.327

8.  Quetiapine cross-reactivity with plasma tricyclic antidepressant immunoassays.

Authors:  E Martin Caravati; Joetta M Juenke; Barbara I Crouch; Kathleen T Anderson
Journal:  Ann Pharmacother       Date:  2005-07-26       Impact factor: 3.154

9.  In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors.

Authors:  Sean Ekins; Jeffrey S Johnston; Praveen Bahadduri; Vanessa M D'Souza; Abhijit Ray; Cheng Chang; Peter W Swaan
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

10.  Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine.

Authors:  K Lim; S M Owens; L Arnold; J C Sacchettini; D S Linthicum
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

View more
  10 in total

1.  A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis.

Authors:  Sean Ekins; Lei Diao; James E Polli
Journal:  Mol Pharm       Date:  2012-02-28       Impact factor: 4.939

2.  Essential metabolites of Mycobacterium tuberculosis and their mimics.

Authors:  Gyanu Lamichhane; Joel S Freundlich; Sean Ekins; Niluka Wickramaratne; Scott T Nolan; William R Bishai
Journal:  mBio       Date:  2011-02-01       Impact factor: 7.867

3.  Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records.

Authors:  Jacob J Hughey; Jennifer M Colby
Journal:  Clin Chem       Date:  2019-10-02       Impact factor: 12.167

4.  Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.

Authors:  Matthew D Krasowski; Sean Ekins
Journal:  J Cheminform       Date:  2014-05-10       Impact factor: 5.514

5.  Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays.

Authors:  Christina D Martinez-Brokaw; Joshua B Radke; Joshua G Pierce; Alexandra Ehlers; Sean Ekins; Kelly E Wood; Jon Maakestad; Jacqueline A Rymer; Kenichi Tamama; Matthew D Krasowski
Journal:  BMC Clin Pathol       Date:  2019-02-18

6.  Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.

Authors:  Matthew D Krasowski; Anthony F Pizon; Mohamed G Siam; Spiros Giannoutsos; Manisha Iyer; Sean Ekins
Journal:  BMC Emerg Med       Date:  2009-04-28

7.  Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction.

Authors:  Matthew D Krasowski; Denny Drees; Cory S Morris; Jon Maakestad; John L Blau; Sean Ekins
Journal:  BMC Clin Pathol       Date:  2014-07-14

8.  A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing.

Authors:  Justine M Reschly-Krasowski; Matthew D Krasowski
Journal:  Acad Pathol       Date:  2018-11-21

9.  Data on hydroxychloroquine interference with urine laboratory testing.

Authors:  Jennie M Kingery; Joshua B Radke; Jon Maakestad; Matthew D Krasowski
Journal:  Data Brief       Date:  2019-11-08

10.  Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case report.

Authors:  Joshua B Radke; Jennie M Kingery; Jon Maakestad; Matthew D Krasowski
Journal:  Toxicol Rep       Date:  2019-10-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.